[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629373":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":28,"responsibleParty":43,"collaborators":20,"id":45,"slug":20,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":20,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":72,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Hospices Civils de Lyon","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PRP injections","EXPERIMENTAL","Single arm receiving autologous platelet-rich plasma injections at Day 0, Day 14 (±1), and Day 28 (±1), with follow-up at Months 3 and 6.",[13],"Biological: Autologous Platelet-Rich Plasma (PRP) Injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Autologous Platelet-Rich Plasma (PRP) Injection","At each injection visit (Day 0, Day 14 ±1, Day 28 ±1), venous blood is collected and processed to obtain autologous PRP using a standardized preparation system. PRP is injected under endoscopic guidance into the superior nasal septum mucosa near the olfactory cleft, up to a total volume of 4 mL per visit. Participants are monitored after each injection and adverse events are recorded.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"MAxime FIEUX, Dr","CONTACT","0033 4 72 66 64 15","+33","maxime.fieux@chu-lyon.fr",[29],{"facility":30,"status":20,"city":31,"state":20,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Hôpital Lyon Sud","Pierre-Bénite","69310","France",{"type":35,"coordinates":36},"Point",[37,38],4.82424,45.70359,{"lat":38,"lon":37},[41],{"name":42,"role":24,"phone":25,"phoneExt":26,"email":27},"Maxime FIEUX, Dr",{"type":44,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100629373",false,"NCT07473830","PANDORA: Evaluation of Platelet-rich Plasma in Non-tumoural Odour Disorders: a Descriptive Pilot Study.","PANDORA","Inclusion Criteria\n\n* Adults with persistent (\\>6 months) non-tumoural olfactory dysfunction: age-related degenerative olfactory dysfunction (DOD) or post-traumatic olfactory dysfunction (DOPT).\n* Objective olfactory impairment confirmed by Sniffin' Sticks Test (TDI ≤ 30.5\u002F48).\n* MRI within the last 6 months after onset excluding tumoural etiology or central cause.\n* Normal nasal endoscopy.\n* Affiliated to a social security system (or equivalent).\n* Written informed consent.\n\nExclusion Criteria\n\n* Inflammatory rhinosinus disease (e.g., nasal polyposis) or granulomatosis with polyangiitis.\n* Coagulation disorder.\n* Brain radiotherapy history or ongoing chemotherapy.\n* Olfactory disorder temporally linked to SARS-CoV-2 infection (delay \\\u003C1 month).\n* History of sinus or skull base surgery (except septoplasty\u002Fturbinoplasty\u002Frhinoseptoplasty).\n* Therapeutic-dose anticoagulants.\n* Refusal to discontinue chronic NSAID use if applicable.\n* Pregnancy\u002Flabor\u002Fbreastfeeding.\n* Vulnerable persons (deprived of liberty; legal protection; etc.).\n* Participation in another interventional study with ongoing exclusion period.","ALL","18 Years","99 Years",{"count":55,"type":56},30,"ESTIMATED","INTERVENTIONAL",[59],"NA","This is a prospective, single-center, single-arm, non-comparative descriptive pilot study evaluating autologous platelet-rich plasma (PRP) injections in adults with persistent (\\>6 months) non-tumoural olfactory dysfunction, either age-related degenerative olfactory dysfunction (DOD) or post-traumatic olfactory dysfunction (DOPT). Participants receive three PRP injections over 4 weeks (Day 0, Day 14, Day 28), with follow-up visits at Month 3 and Month 6 after the first injection. Olfactory function is assessed using the Sniffin' Sticks Test (TDI score). Patient-reported outcomes include SNOT-22 and a visual analog scale (VAS) for perceived olfactory impairment. Safety is assessed through adverse event collection.",[62,63,64],"Olfactory Dysfunction","Post-traumatic Olfactory Dysfunction","Age-related Degenerative Olfactory Dysfunction",[66,67,68,69,70,71],"Platelet-rich plasma","PRP","Sniffin' Sticks","Olfactory cleft","Hyposmia","Anosmia","NOT_YET_RECRUITING","2026-03-17",{"date":75,"type":76},"2026-03-20","ACTUAL",{"date":78,"type":56},"2026-05",{"date":80,"type":56},"2028-05",{"name":5,"class":6},1]